Neighborhood disadvantage, or living in a poorer region, was linked to significantly shorter survival time for ALS patients ...

IFB-088 (icerguastat) was safe and significantly slowed disease progression in certain people with ALS in a Phase 2 clinical trial.

A trial that will test a noninvasive device called MyoRegulator as a treatment for ALS was cleared to start enrolling ...

After more than a decade of living with her husband's ALS, columnist Kristin Neva has found the equipment to be helpful in ...

Repeated brain injury resulted in SOD1-ALS mice showing greater weight loss, an earlier tremor in the hind limbs, and ...

Ncardia’s iPSC-derived microglia may aid ALS research and help to screen new therapies that target inflammation in ALS.

Qure is planning soon to start enrolling patients in a second dose group as part of a clinical trial testing AMT-162 for SOD1 ...

Neuropeutics is collaborating with LifeArc on a small molecule therapy that reportedly lowered TDP-43 clumping in an animal ...

Masitinib is an oral inhibitor of tyrosine kinases, enzymes important for immune cells thought to drive ALS inflammation and ...

Columnist Dagmar Munn turns to affirmations and positive self-talk on those occasional days when she feels shut down.